Stratification of nucleoside analog chemotherapy using 1-(2′-deoxy- 2′- 18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2′-deoxy-2′- 18F-fluoro-β-L-arabinofuranosyl)-5- methylcytosine PET

Journal of Nuclear Medicine

Volumn 53, Issue 2, 2012, Pages 275-280

  Lee, Jason T ^a   Campbell, Dean O ^a   Satyamurthy, Nagichettiar ^a   Czernin, Johannes ^a   Radu, Caius G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

18F FAC and L 18F FMAC PET; Cytidine deaminase (CDA); Deoxycytidine kinase (dCK); Deoxyribonucleoside salvage metabolism; Personalized cancer therapy

Indexed keywords

1 (2' DEOXY 2' FLUORO BETA ARABINOFURANOSYL) 5 METHYLCYTOSINE F 18; 1 (2' DEOXY 2' FLUORO BETA ARABINOFURANOSYL)CYTOSINE F 18; C 7495; CLOFARABINE; CYTIDINE DEAMINASE; DEOXYCYTIDINE KINASE; GEMCITABINE; TRACER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CELL VIABILITY; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TUMOR LEVEL; ENZYME ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE TRACING; LEUKEMIA; LEUKEMIA CELL; MOLECULAR IMAGING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ADENINE NUCLEOTIDES; ANIMALS; ARABINONUCLEOSIDES; CELL LINE, TUMOR; CYTARABINE; CYTIDINE DEAMINASE; CYTOSINE; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; FLUORINE RADIOISOTOPES; GENE EXPRESSION REGULATION, NEOPLASTIC; LEUKEMIA, LYMPHOID; MICE; POSITRON-EMISSION TOMOGRAPHY; TREATMENT OUTCOME;

EID: 84863054683     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.090407     Document Type: Article

References (21)

1. Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer. 2002;94:902-910. (Pubitemid 34150843)
2. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006;24:3946-3952. (Pubitemid 46630743)
3. 18F]-labeled 2′- deoxycytidine analog. Nat Med. 2008;14:783-788.
4. Laing RE, Walter MA, Campbell DO, et al. Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography. Proc Natl Acad Sci USA. 2009;106:2847-2852.
5. Jordheim LP, Dumontet C. Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. Biochim Biophys Acta. 2007;1776:138-159.
6. Ho DH. Distribution of kinase and deaminase of 1-beta-D- arabinofuranosylcytosine in tissues of man and mouse. Cancer Res. 1973;33:2816-2820.
7. Lamba JK. Genetic factors influencing cytarabine therapy. Pharmacogenomics. 2009;10:1657-1674.
8. Bonate PL, Arthaud L, Cantrell WR Jr, Stephenson K, Secrist JA 3rd, Weitman S. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov. 2006;5:855-863. (Pubitemid 44480539)
9. Shu CJ, Campbell DO, Lee JT, et al. Novel PET probes specific for deoxycytidine kinase. J Nucl Med. 2010;51:1092-1098.
10. Jordheim LP, Cros E, Gouy MH, et al. Characterization of a gemcitabine-resistant murine leukemic cell line: reversion of in vitro resistance by a mononucleotide prodrug. Clin Cancer Res. 2004;10:5614-5621. (Pubitemid 39100503)
11. Hawley RG, Lieu FH, Fong AZ, Hawley TS. Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1994;1:136-138.
12. Radu CG, Witte ON, Nair-Gill E, Satyamurthy N, Shu CJ, Czernin J, inventors; The Regents of the University of California, assignee. Positron emission tomography probes for imaging immune activation and selected cancers. US patent PCT WO 2009/038795 A2. March 26, 2009.
13. Sreekumar A, Poisson LM, Rajendiran TM, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457: 910-914.
14. Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology: a review. Clin Cancer Res. 2009;15:431-440.
15. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11:85-95.
16. Ueno H, Kiyosawa K, Kaniwa N. Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? Br J Cancer. 2007;97:145-151. (Pubitemid 47057479)
17. Sebastiani V, Ricci F, Rubio-Viqueira B, et al. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res. 2006;12:2492-2497.
18. Bengala C, Guarneri V, Giovannetti E, et al. Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma. Br J Cancer. 2005;93:35-40. (Pubitemid 41076250)
19. Damaraju VL, Damaraju S, Young JD, et al. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene. 2003;22:7524-7536. (Pubitemid 37487174)
20. Bergman AM, Eijk PP, Ruiz van Haperen VW, et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res. 2005;65:9510-9516. (Pubitemid 41508021)
21. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324:1457-1461.